AIM VACCINE CO., LTD. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.46 HKD | +2.17% |
|
+1.56% | +7.77% |
| Mar. 28 | Aim Vaccine Submits Pre-Applications for Clinical Trials for Two Vaccines; Shares Up 3% | MT |
| Mar. 28 | Aim Vaccine's Loss Quadruples in 2023 as Revenue Slips 6%; Shares Up 3% | MT |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- The company is in debt and has limited leeway for investment
Ratings chart - Surperformance
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +7.77% | 1.27B | - | ||
| -2.35% | 89.08B | A- | ||
| +2.76% | 40.9B | A- | ||
| -12.92% | 32.25B | B- | ||
| +54.69% | 25.14B | A | ||
| -16.51% | 15.39B | C | ||
| -8.27% | 11.91B | B- | ||
| -42.60% | 11.89B | B | ||
| -12.82% | 11.64B | D+ | ||
| +7.34% | 9.03B | B+ |
Investor Rating
Trading Rating
-
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
-
Finances
Valuation
P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
-
4 months EPS revision
-
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
-
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 6660 Stock
- Ratings AIM Vaccine Co., Ltd.
